File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Risk Factors for Longer-Term Mortality in Discharged Patients with Dementia and SARS-CoV-2 Infection: A Matched Case-Control Study

TitleRisk Factors for Longer-Term Mortality in Discharged Patients with Dementia and SARS-CoV-2 Infection: A Matched Case-Control Study
Authors
KeywordsDementia
longer-term mortality
post-acute COVID-19
SARS-CoV-2
Issue Date2023
Citation
Journal of Alzheimer S Disease, 2023, v. 92, n. 1, p. 295-309 How to Cite?
AbstractBackground: Persisting symptoms and increased mortality after SARS-CoV-2 infection has been described in COVID-19 survivors. Objective: We examined longer-term mortality in patients with dementia and SARS-CoV-2 infection. Methods: A retrospective matched case-control study of 165 patients with dementia who survived an acute hospital admission with COVID-19 infection, and 1325 patients with dementia who survived a hospital admission but without SARS-CoV-2 infection. Potential risk factors investigated included socio-demographic factors, clinical features, and results of investigations. Data were fitted using a Cox proportional hazard model. Results: Compared to patients with dementia but without SARS-CoV-2 infection, people with dementia and SARS-CoV-2 infection had a 4.4-fold risk of death (adjusted hazard ratio [aHR] = 4.44, 95% confidence interval [CI] 3.13-6.30) even beyond the acute phase of infection. This excess mortality could be seen up to 125 days after initial recovery but was not elevated beyond this time. Risk factors for COVID-19-associated mortality included prescription of antipsychotics (aHR = 3.06, 95% CI 1.40-6.69) and benzodiazepines (aHR = 3.00, 95% CI 1.28-7.03). Abnormalities on investigation associated with increased mortality included high white cell count (aHR = 1.21, 95% CI 1.04-1.39), higher absolute neutrophil count (aHR = 1.28, 95% CI 1.12-1.46), higher C-reactive protein (aHR = 1.01, 95% CI 1.00-1.02), higher serum sodium (aHR = 1.09, 95% CI 1.01-1.19), and higher ionized calcium (aHR = 1.03, 95% CI 1.00-1.06). The post-acute COVID mortality could be modeled for the first 120 days after recovery with a balanced accuracy of 87.2%. Conclusion: We found an increased mortality in patients with dementia beyond the acute phase of illness. We identified several investigation results associated with increased mortality, and increased mortality in patients prescribed antipsychotics or benzodiazepines.
Persistent Identifierhttp://hdl.handle.net/10722/368729
ISSN
2023 Impact Factor: 3.4
2023 SCImago Journal Rankings: 1.172

 

DC FieldValueLanguage
dc.contributor.authorChen, Shanquan-
dc.contributor.authorCardinal, Rudolf N.-
dc.contributor.authorAuckland, Kathryn-
dc.contributor.authorGräf, Stefan-
dc.contributor.authorO'Brien, John T.-
dc.contributor.authorUnderwood, Benjamin R.-
dc.date.accessioned2026-01-16T02:37:48Z-
dc.date.available2026-01-16T02:37:48Z-
dc.date.issued2023-
dc.identifier.citationJournal of Alzheimer S Disease, 2023, v. 92, n. 1, p. 295-309-
dc.identifier.issn1387-2877-
dc.identifier.urihttp://hdl.handle.net/10722/368729-
dc.description.abstractBackground: Persisting symptoms and increased mortality after SARS-CoV-2 infection has been described in COVID-19 survivors. Objective: We examined longer-term mortality in patients with dementia and SARS-CoV-2 infection. Methods: A retrospective matched case-control study of 165 patients with dementia who survived an acute hospital admission with COVID-19 infection, and 1325 patients with dementia who survived a hospital admission but without SARS-CoV-2 infection. Potential risk factors investigated included socio-demographic factors, clinical features, and results of investigations. Data were fitted using a Cox proportional hazard model. Results: Compared to patients with dementia but without SARS-CoV-2 infection, people with dementia and SARS-CoV-2 infection had a 4.4-fold risk of death (adjusted hazard ratio [aHR] = 4.44, 95% confidence interval [CI] 3.13-6.30) even beyond the acute phase of infection. This excess mortality could be seen up to 125 days after initial recovery but was not elevated beyond this time. Risk factors for COVID-19-associated mortality included prescription of antipsychotics (aHR = 3.06, 95% CI 1.40-6.69) and benzodiazepines (aHR = 3.00, 95% CI 1.28-7.03). Abnormalities on investigation associated with increased mortality included high white cell count (aHR = 1.21, 95% CI 1.04-1.39), higher absolute neutrophil count (aHR = 1.28, 95% CI 1.12-1.46), higher C-reactive protein (aHR = 1.01, 95% CI 1.00-1.02), higher serum sodium (aHR = 1.09, 95% CI 1.01-1.19), and higher ionized calcium (aHR = 1.03, 95% CI 1.00-1.06). The post-acute COVID mortality could be modeled for the first 120 days after recovery with a balanced accuracy of 87.2%. Conclusion: We found an increased mortality in patients with dementia beyond the acute phase of illness. We identified several investigation results associated with increased mortality, and increased mortality in patients prescribed antipsychotics or benzodiazepines.-
dc.languageeng-
dc.relation.ispartofJournal of Alzheimer S Disease-
dc.subjectDementia-
dc.subjectlonger-term mortality-
dc.subjectpost-acute COVID-19-
dc.subjectSARS-CoV-2-
dc.titleRisk Factors for Longer-Term Mortality in Discharged Patients with Dementia and SARS-CoV-2 Infection: A Matched Case-Control Study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3233/JAD-221093-
dc.identifier.pmid36744344-
dc.identifier.scopuseid_2-s2.0-85150079383-
dc.identifier.volume92-
dc.identifier.issue1-
dc.identifier.spage295-
dc.identifier.epage309-
dc.identifier.eissn1875-8908-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats